Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...

Abby Jones’ first stop of the day delivering medication was the home of 90-year-old Sarah Campbell Kier. “Come in!” yelled ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

We recently published a list of 10 Companies Reflect Market Decline. In this article, we are going to take a look at where ...

SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

A recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit managers (PBMs) are accused of significantly inflating the cost of ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.